Rice Hall James & Associates LLC Acquires 119,306 Shares of OptimizeRx Co. (NASDAQ:OPRX)

Rice Hall James & Associates LLC raised its holdings in OptimizeRx Co. (NASDAQ:OPRX) by 24.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 615,441 shares of the company’s stock after acquiring an additional 119,306 shares during the quarter. Rice Hall James & Associates LLC owned about 3.36% of OptimizeRx worth $4,751,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Summit Securities Group LLC bought a new position in OptimizeRx in the second quarter valued at approximately $25,000. Connors Investor Services Inc. boosted its stake in OptimizeRx by 15.1% in the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock valued at $191,000 after acquiring an additional 2,500 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in OptimizeRx by 283.6% in the first quarter. BNP Paribas Financial Markets now owns 27,910 shares of the company’s stock valued at $339,000 after acquiring an additional 20,634 shares during the last quarter. Squarepoint Ops LLC bought a new position in OptimizeRx in the second quarter valued at approximately $282,000. Finally, Rhumbline Advisers boosted its stake in OptimizeRx by 9.2% in the second quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock valued at $315,000 after acquiring an additional 2,658 shares during the last quarter. 76.47% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. B. Riley assumed coverage on shares of OptimizeRx in a report on Thursday, July 25th. They issued a “buy” rating and a $18.50 target price on the stock. Royal Bank of Canada cut their target price on shares of OptimizeRx from $17.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, August 16th. Finally, Barclays cut their target price on shares of OptimizeRx from $15.00 to $11.00 and set an “equal weight” rating on the stock in a report on Monday, August 12th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $14.50.

OptimizeRx Stock Down 4.7 %

Shares of NASDAQ:OPRX opened at $5.22 on Friday. OptimizeRx Co. has a 12 month low of $5.21 and a 12 month high of $16.65. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.07 and a current ratio of 3.07. The company’s fifty day simple moving average is $7.18 and its 200 day simple moving average is $9.30.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.11. OptimizeRx had a negative net margin of 21.53% and a negative return on equity of 5.97%. The firm had revenue of $18.81 million for the quarter, compared to analyst estimates of $20.47 million. As a group, equities research analysts predict that OptimizeRx Co. will post -0.33 earnings per share for the current fiscal year.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.